// App-Quantinova.ai

2337 : Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Researchers

Presenter

  • Christine G Kohn

Principal Investigators

  • Erin R Weeda

  • W Frank Peacock

  • Gregory J Fermann

  • Christopher W. Baugh

  • Philip S Wells

  • Veronica Ashton

  • Concetta Crivera

  • Peter Wildgoose

  • Jeff Schein

  • Craig I Coleman

Medical Centers

  • Hematology, Ottawa Hospital, Ottawa, ON, Canada

  • Evidence-based Practice Center, UCONN/Hartford Hospital, Hartford, CT

  • Harvard Medical School, Boston, MA

  • University of Cincinatti Medical Center, Cincinatti, OH

  • Pediatric Hospital Medicine, Baylor College of Medicine, Houston, TX

  • School of Pharmacy, University of Saint Joseph, Hartford, CT

  • School of Pharmacy, University of Connecticut, Storrs, CT

Locations

  • United States

  • Canada

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Pulmonary embolism

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Hydroxyzine

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved